Your session is about to expire
← Back to Search
Azithromycin 500mg for Premature Rupture of Membranes (ADAPT Trial)
Phase 4
Waitlist Available
Led By Rupsa C Boelig, MD
Research Sponsored by Thomas Jefferson University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months
Awards & highlights
ADAPT Trial Summary
This trial is to assess how well azithromycin works in pregnant women with PPROM.
Eligible Conditions
- Premature Rupture of Membranes
ADAPT Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 3 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Azithromycin trough in amniotic fluid
Secondary outcome measures
Histologic chorioamnionitis
IL-6 in amniotic fluid
IL-8 in cord blood
+5 moreADAPT Trial Design
2Treatment groups
Active Control
Group I: Azithromycin 500mgActive Control1 Intervention
500mg azithromycin PO daily for seven days
Group II: Azithromycin 1000mgActive Control1 Intervention
1000mg azithromycin PO once at admission
Find a Location
Who is running the clinical trial?
Christiana Care Health ServicesOTHER
114 Previous Clinical Trials
105,645 Total Patients Enrolled
Thomas Jefferson UniversityLead Sponsor
444 Previous Clinical Trials
145,618 Total Patients Enrolled
Rupsa C Boelig, MDPrincipal InvestigatorThomas Jefferson University
4 Previous Clinical Trials
431 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger